HAEMOLYTIC DISEASE OF THE FETUS AND NEWBORN (HDFN) – CASE REPORT
DOI:
https://doi.org/10.6016/ZdravVestn.1890Keywords:
RhD immunization, hemolytic disease of the fetus and newborn, prevention of RhD immunization, anti-D antibody titer, test ADCC, exchange transfusion, case reportAbstract
Background. Hemolytic disease of the fetus and newborn (HDFN) develops because of the passage of maternal erythrocyte alloantibodies through the placenta. These antibodies cause a reduction of the erythrocyte life span in the fetus and newborn. This severe form of the disease is most commonly caused by anti-D antibodies. Besides those, the hemolytic disease can also be caused by anti-K, anti-c, anti-E, anti-A, anti-B and some other antibodies.
Methods and material. A case of a pregnant woman who has been pregnant four times is presented. During the first pregnancy, she developed anti-D erythrocyte antibodies, and after the third pregnancy also additional anti-C antibodies. During the first pregnancy, hemolytic disease of fetus led to the intrauterine death of the fetus. The second child died one day after birth. The third and fourth fetuses required several intrauterine exchange transfusions due to high titers and great hemolytic activity of anti-D antibodies. In both newborns, exchange transfusions had to be performed after birth, and both received additional transfusions of concentrated erythrocytes because of anemia.
Conclusions. HDFN is a severe disorder that can be successfully prevented with appropriate legalized measures.
Downloads
References
Mollison PL, Engelfriet CP, Contreras M. Haemolytic disease of the fetus and newborn. In: Mollison PL, Engelfriet CP, Contreras M eds. Blood transfusion in clinical medicine. 10th ed. Oxford: Blackwell Science, 1997: 390–424.
Bowman JM. Historical overview: Haemolytic disease of the fetus and newborn. In: Kennedy HS, Wilson SM, Kelton JG eds. Perinatal transfusion medicine. Arlington: AABB, 1990: 1–52.
Carreras-Versico LA, Torres OW, Virgilio OS, Pizzolato M. Mild haemolytic disease of the newborn due to Anti-Lewis a. Vox Sang 1993; 64: 194–5.
Bharucha ZS, Joshi SR, Bhatia HM. Haemolytic disease of the newborn due to Anti-Leb. Vox Sang 1981; 41: 36–9.
Bricl I, Vogler A. Preprečevanje imunizacij anti-D z imunoprofilakso RhD. Med Razgl 2000; 39: Suppl 4–7: 195–8.
Vengelen-Tyler V. Perinatal concerns in transfusion practice. In: VengelenTyler V ed. Technical manual. Bethesda: AABB, 1999: 495–512.
Stedman CM, Baudin JC, White CA, Shanon-Cooper E. Use of the erithrocyte rosette test to screen for excessive fetomaternal haemorrhage in Rh negative women. Am J Obstet Gynecol 1986; 154: 1363–9.
Napier JAF. Haemolytic disease of the newborn. In: Napier JAF ed. Handbook of blood transfusion therapy. 2nd ed. Chichester, New York, Toronto, Brisbane, Singapore: John Wiley & Sons, 1995: 287–315.
Urbaniak SJ. The scientific basis of antenatal prophylaxis. Br J Obstet Gynaecol 1998; 105: Suppl 18: 11–8.
Garner SF, Gorick BD, Lai WYY et al. Prediction of the severity of the haemolytic disease of the newborn. Vox Sang 1995; 68: 169–76.
Larson PJ, Thorp JM, Miller RC, Hoffman M. The monocyte monolayer assay: a non-invasive technique for predicting the severity of in utero haemolysis. Am J Perinat 1995; 12: 157–60.
Skupski DW, Wolf CFW, Bussel JM. Fetal and perinatal transfusion therapy. In: Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG eds. Clinical practice of transfusion medicine. 3rd ed. New York: Churchill Livingstone, 1996: 607–29.
Lapierre Y, Rigal D, Adam J et al. The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion 1990; 30: 109–13.
Downloads
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
